7,580.07

-140.32

-1.82%

51,770.31

-572.29

-1.09%

25,437.00

-747.70

-2.86%

2,811.84

-47.38

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,848.14

+363.27

+0.47%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCID USD

Avenue Therapeutics, Inc. (ATXI)

0.4279 +0.0479 (+12.60%)

At close: October 30 at 5:00:00 PM EDT

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

GlobeNewswire 8mo ago

ATXI
+12.60%
FBIO

FBIOP
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

GlobeNewswire 11mo ago

AXSM

FBIO

FBIOP
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

GlobeNewswire 11mo ago

AZN

AZNCF

ATXI
+12.60%

Mobilize your Website

View Site in Mobile | Classic

Share by: